宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688247 宣泰医药

已收盘 09-30 15:00:00

{"stockData":{"symbol":"688247","market":"SH","secType":"STK","nameCN":"宣泰医药","latestPrice":9.75,"timestamp":1727679600000,"preClose":8.55,"halted":0,"volume":6210861,"delay":0,"floatShares":142000000,"shares":453000000,"eps":0.204,"marketStatus":"已收盘","marketStatusCode":5,"change":1.2,"latestTime":"09-30 15:00:00","open":8.99,"high":9.81,"low":8.76,"amount":57759400,"amplitude":0.1228,"askPrice":9.75,"askSize":179,"bidPrice":9.74,"bidSize":106,"shortable":0,"etf":0,"ttmEps":0.204,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1728351000000},"adr":0,"adjPreClose":8.55,"symbolType":"stock_kcb","openAndCloseTimeList":[[1727659800000,1727667000000],[1727672400000,1727679600000]],"highLimit":9.41,"lowLimit":7.7,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":453340000,"pbRate":3.65,"roa":"--","roe":"4.47%","epsLYR":0.13,"committee":-0.527523,"marketValue":4420000000,"floatMarketCap":1388000000,"peRate":47.794119,"changeRate":0.1404,"turnoverRate":0.0436,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-10-08。","afterMarket":{"amount":0,"volume":0,"close":9.75,"buyVolume":0,"sellVolume":0,"time":1727681637153,"indexStatus":"已收盘 09-30 15:30:00","preClose":8.55}},"requestUrl":"/m/hq/s/688247","defaultTab":"news","newsList":[{"id":"2471815255","title":"宣泰医药创1个月新高 获主力净流入39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2471815255","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471815255?lang=zh_cn&edition=full","pubTime":"2024-09-30 09:30","pubTimestamp":1727659803,"startTime":"0","endTime":"0","summary":"09月30日，宣泰医药股价大幅上涨，截至09点30分，宣泰医药上涨5.26%，报9.00元/股，创近1个月新高，成交53万元，换手率0.04%，振幅0.12%。资金动向截止发稿，宣泰医药获得主力净流入39万元，其中超大单流出9万元，大单流入48万元。主营业务及业绩宣泰医药公司主营业务为仿制药的研发、生产和销售以及CRO服务。最新财报显示，今年中报，宣泰医药实现营业收入2.18亿元，同比增长96.81%，净利润为5,415.33万元，同比增长137.60%，基本每股收益为0.12元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930094318ab66eb63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930094318ab66eb63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2469136815","title":"宣泰医药大幅上涨 峡江县生物医药产业迅猛发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2469136815","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469136815?lang=zh_cn&edition=full","pubTime":"2024-09-23 09:38","pubTimestamp":1727055491,"startTime":"0","endTime":"0","summary":"09月23日，宣泰医药股价大幅上涨，截至09点38分，宣泰医药上涨5.23%，报8.05元/股，成交434万元，换手率0.39%，振幅4.58%。消息解读2023年，江西省吉安市峡江县的生物医药全产业链实现营收151.4亿元，是2016年的2.5倍。峡江县有各类生物医药企业177家、生物医药高层次人才170余名。资金动向截止发稿，宣泰医药获得主力净流入139万元。主营业务及业绩宣泰医药公司主营业务为仿制药的研发、生产和销售以及CRO服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240923093848ab6539e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240923093848ab6539e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688247","399441","161726"],"gpt_icon":0},{"id":"2468374981","title":"宣泰医药：公司产品达格列净二甲双胍缓释片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2468374981","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468374981?lang=zh_cn&edition=full","pubTime":"2024-09-18 15:45","pubTimestamp":1726645552,"startTime":"0","endTime":"0","summary":"9月18日，宣泰医药公告，公司向国家药品监督管理局申报的达格列净二甲双胍缓释片产品已获得正式批准，为该品种国内首家获批的仿制药。该产品用于治疗2型糖尿病，原研由阿斯利康公司研发，于2023年6月在中国获批上市，已纳入医保乙类支付。公司已向美国食品药品监督管理局递交该产品的新药简略申请，并积极开拓南美、东南亚、中东等国际市场。文章来源：每日经济新闻原标题：宣泰医药：公司产品达格列净二甲双胍缓释片获得药品注册证书","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409181559149f047cd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409181559149f047cd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2468379371","title":"宣泰医药(688247.SH)产品达格列净二甲双胍缓释片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2468379371","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468379371?lang=zh_cn&edition=full","pubTime":"2024-09-18 15:42","pubTimestamp":1726645360,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)公告，近日，公司收到国家药品监督管理局的通知，公司向国家药品监督管理局申报的达格列净二甲双胍缓释片产品已获得正式批准，为该品种国内首家获批的仿制药。公司获批的达格列净二甲双胍缓释片，为该品种国内首家获批的仿制药，用于治疗2型糖尿病。原研由阿斯利康公司研发，于2023年6月在中国获批上市，已纳入医保乙类支付。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1184048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2464492007","title":"宣泰医药：累计回购约419万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2464492007","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464492007?lang=zh_cn&edition=full","pubTime":"2024-09-02 15:46","pubTimestamp":1725263200,"startTime":"0","endTime":"0","summary":"每经AI快讯，宣泰医药 9月2日晚间发布公告称，截至2024年8月31日，公司通过上海证券交易所交易系统以集中竞价交易方式已累计回购股份约419万股，占公司总股本约4.53亿股的比例为0.92%，购买的最高价为8.98元/股，最低价为8元/股，支付的资金总额为人民币约3501万元。2023年1至12月份，宣泰医药的营业收入构成为：医药制造业占比99.84%。截至发稿，宣泰医药市值为36亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090215471195db36ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090215471195db36ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2464583009","title":"宣泰医药大跌5.08% 主力资金净流出86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464583009","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464583009?lang=zh_cn&edition=full","pubTime":"2024-09-02 14:56","pubTimestamp":1725260204,"startTime":"0","endTime":"0","summary":"09月02日，宣泰医药股价大幅下跌，截至14点56分，宣泰医药下跌5.08%，报7.85元/股，成交3714万元，换手率3.25%。资金动向截止发稿，宣泰医药获得主力净流出86万元，其中超大单流出75万元，大单流出9万元。主营业务及业绩宣泰医药公司主营业务为仿制药的研发、生产和销售以及CRO服务。最新财报显示，今年中报，宣泰医药实现营业收入2.18亿元，同比增长96.81%，净利润为5,415.33万元，同比增长137.60%，基本每股收益为0.12元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240902145658ab616436&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240902145658ab616436&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2463773246","title":"宣泰医药(688247)6月30日股东户数0.7万户，较上期减少4.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463773246","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463773246?lang=zh_cn&edition=full","pubTime":"2024-08-31 17:04","pubTimestamp":1725095057,"startTime":"0","endTime":"0","summary":"证券之星消息，近日宣泰医药披露，截至2024年6月30日公司股东户数为6994.0户，较3月31日减少320.0户，减幅为4.38%。在化学制药行业个股中，宣泰医药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.2万户。从股价来看，2024年3月31日至2024年6月30日，宣泰医药区间跌幅为1.2%，在此期间股东户数减少320.0户，减幅为4.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083100013468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2463731833","title":"宣泰医药(688247.SH)发布上半年业绩，净利润5415.33万元，同比增长137.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463731833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463731833?lang=zh_cn&edition=full","pubTime":"2024-08-30 20:01","pubTimestamp":1725019275,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布2024年半年度报告，公司营业收入2.18亿元，同比增长96.81%;归属于上市公司股东的净利润5415.33万元，同比增长137.60%;归属于上市公司股东的扣除非经常性损益的净利润4879.34万元，同比增长167.97%;基本每股收益0.12元/股。拟向全体股东每10股派发现金红利0.25元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1176935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247"],"gpt_icon":0},{"id":"2463678679","title":"【宣泰医药：2024年半年度净利润同比增长137.60%】金十数据8月30日讯，宣泰医药公告，公司2024年半年度实现营业收入2.","url":"https://stock-news.laohu8.com/highlight/detail?id=2463678679","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463678679?lang=zh_cn&edition=full","pubTime":"2024-08-30 17:50","pubTimestamp":1725011450,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2463724023","title":"宣泰医药8月28日获融资净买入21万元 环比增加771.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463724023","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463724023?lang=zh_cn&edition=full","pubTime":"2024-08-30 10:00","pubTimestamp":1724983209,"startTime":"0","endTime":"0","summary":"8月28日，宣泰医药获融资净买入21万元，环比上一交易日增加771.82%。其中，融资买入57万元，融资偿还35万元。融券方面，融券卖出0.00万股，当前融券余量为1.27万股。A股市场共有3358股获融资净买入，宣泰医药净买入额排名第1074。股市有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024083010015995d19a4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024083010015995d19a4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2463420513","title":"熊去氧胆酸概念盘中拉升，宣泰医药涨4.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463420513","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463420513?lang=zh_cn&edition=full","pubTime":"2024-08-29 11:01","pubTimestamp":1724900463,"startTime":"0","endTime":"0","summary":"08月29日，熊去氧胆酸概念盘中拉升，截至11点00分，熊去氧胆酸概念整体指数上涨1.06%，报907.970点。从个股上来看，该概念的成分股中，宣泰医药涨4.40%，阿拉丁、川宁生物、吉贝尔涨幅居前。从资金上来看，截止发稿，熊去氧胆酸概念主力净流入为-2269.85万，其中川宁生物受到资金热捧，主力净流入440.07万；拉长时间线来看，该板块近20日主力资金净流入-11.10亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240829110103af9784bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240829110103af9784bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2462498264","title":"宣泰医药8月23日获融资净买入9万元 环比增加438.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462498264","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462498264?lang=zh_cn&edition=full","pubTime":"2024-08-26 10:00","pubTimestamp":1724637608,"startTime":"0","endTime":"0","summary":"8月23日，宣泰医药获融资净买入9万元，环比上一交易日增加438.12%。其中，融资买入56万元，融资偿还47万元。融券方面，融券卖出0.00万股，当前融券余量为1.27万股。A股市场共有1603股获融资净买入，宣泰医药净买入额排名第532。股市有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082610001995c33e96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082610001995c33e96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2462548983","title":"宣泰医药（688247）226.7万股限售股将于8月26日解禁，占总股本0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462548983","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462548983?lang=zh_cn&edition=full","pubTime":"2024-08-26 08:06","pubTimestamp":1724630768,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，宣泰医药于8月26日将有226.7万股限售股份解禁，为公司首发战略配售股份，占公司总股本0.5%。本次解禁后，公司还有3.11亿股限售股份，占总股本68.61%。宣泰医药主营业务：主要从事仿制药的研发、生产和销售以及CRO服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082600001554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2462615008","title":"梦想从张江起航，宣泰医药让“高性价比”仿制药走向全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2462615008","media":"浦东发布","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462615008?lang=zh_cn&edition=full","pubTime":"2024-08-25 10:22","pubTimestamp":1724552548,"startTime":"0","endTime":"0","summary":"从创立之日起，上海宣泰医药科技股份有限公司就选择张江作为“梦想”开始的地方。宣泰医药于2022年登陆科创板，至今已有2年时间。上市以来，研发和创新始终是宣泰医药的关键词。郭明洁表示，依托于研发的高投入，截至2023年底，宣泰医药已取得70项知识产权。CRO、CMO方面，郭明洁称，在张江药谷的全产业链服务优势之下，宣泰医药会扎扎实实服务好本土创新企业，发挥中国工程师红利优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408251025069f51794f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408251025069f51794f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2461175894","title":"熊去氧胆酸概念盘中跳水，宣泰医药跌1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461175894","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461175894?lang=zh_cn&edition=full","pubTime":"2024-08-21 14:16","pubTimestamp":1724220966,"startTime":"0","endTime":"0","summary":"08月21日，熊去氧胆酸概念盘中跳水，截至14点16分，熊去氧胆酸概念整体指数下跌2.01%，报900.660点。从个股上来看，该概念的成分股中，宣泰医药跌1.21%，阿拉丁、吉贝尔、华润双鹤跌幅居前。从资金上来看，截止发稿，熊去氧胆酸概念主力净流入为-9026.27万，其中海辰药业受到资金热捧，主力净流入119.91万；拉长时间线来看，该板块近20日主力资金净流入-8.97亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082114160696826f7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082114160696826f7f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2459933362","title":"宣泰医药(688247.SH)226.7万股限售股将于8月26日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2459933362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459933362?lang=zh_cn&edition=full","pubTime":"2024-08-16 17:14","pubTimestamp":1723799681,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)公告，公司本次股票上市流通总数为226.7万股，上市流通日期为2024年8月26日(2024年8月25日是非交易日，上市流通日期顺延至2024年8月26日)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2458304351","title":"熊去氧胆酸概念盘中跳水，宣泰医药跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458304351","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458304351?lang=zh_cn&edition=full","pubTime":"2024-08-09 09:41","pubTimestamp":1723167671,"startTime":"0","endTime":"0","summary":"08月09日，熊去氧胆酸概念盘中跳水，截至09点41分，熊去氧胆酸概念整体指数下跌1.10%，报914.150点。从个股上来看，该概念的成分股中，宣泰医药跌0.91%，九典制药、千红制药、上海医药跌幅居前。从资金上来看，截止发稿，熊去氧胆酸概念主力净流入为-4640.92万，其中新华制药受到资金热捧，主力净流入190.31万；拉长时间线来看，该板块近20日主力资金净流入-6.89亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809094111af96b4ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809094111af96b4ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2457614837","title":"北向资金8月2日净买入宣泰医药20.73万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2457614837","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457614837?lang=zh_cn&edition=full","pubTime":"2024-08-05 09:30","pubTimestamp":1722821440,"startTime":"0","endTime":"0","summary":"8月2日, 北向资金增持宣泰医药20.73万股，连续3日增持。截止当日收盘，沪股通共持有宣泰医药63.83万股，占流通股0.45%。沪股通增持金额前五个股分别为澜起科技、中国神华、中国中车、工商银行、中国太保。宣泰医药近5个交易日上涨6.88%，沪股通累计增持44.63万股；近20个交易日上涨8.06%，沪股通累计增持11.99万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805093354957d78ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805093354957d78ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2455318760","title":"宣泰医药：累计回购约419万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2455318760","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455318760?lang=zh_cn&edition=full","pubTime":"2024-07-31 19:52","pubTimestamp":1722426720,"startTime":"0","endTime":"0","summary":"每经AI快讯，宣泰医药7月31日晚间发布公告称，截至2024年7月31日，公司通过上海证券交易所交易系统以集中竞价交易方式已累计回购股份约419万股，占公司总股本约4.53亿股的比例为0.92%，购买的最高价为8.98元/股，最低价为8元/股，支付的资金总额为人民币约3501万元。2023年1至12月份，宣泰医药的营业收入构成为：医药制造业占比99.84%。每经头条（nbdtoutiao）——“靠增员获得的收入越来越少”“现在一张保单顶原来一个分公司一年的业务量”⋯⋯人海战术红利结束后，精英代理人正受险企青睐(记者 蔡鼎)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024073119523695715875&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024073119523695715875&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2455006845","title":"积极布局全球化，宣泰医药加快出海步伐","url":"https://stock-news.laohu8.com/highlight/detail?id=2455006845","media":"同壁财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455006845?lang=zh_cn&edition=full","pubTime":"2024-07-29 12:37","pubTimestamp":1722227849,"startTime":"0","endTime":"0","summary":"据悉，泊沙康唑肠溶片目前已在澳大利亚、新加坡、沙特阿拉伯、以色列与加拿大获批上市。一直以来，宣泰医药始终坚持产品国际化战略，致力于成为具有竞争力的国际化制药企业。不久前，宣泰医药亮相CPHI东南亚展会，与来自全球数十个国家的400多家参展商和近万名海内外行业人士，深入交流探讨，共话业务合作新机遇。未来，吴华峰表示公司将继续深耕仿制药和CDMO领域，牢牢把握国际化发展机遇，加快产品商业化步伐，积极进行全球布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072912393695647eb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072912393695647eb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688247","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-08-25","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路780号7层709室","stockEarnings":[{"period":"1week","weight":0.2728},{"period":"1month","weight":0.179},{"period":"3month","weight":0.179},{"period":"6month","weight":0.1461},{"period":"1year","weight":-0.1352},{"period":"ytd","weight":-0.1076}],"companyName":"上海宣泰医药科技股份有限公司","boardCode":"AI0027","perCapita":"20349股","boardName":"医药制造业","registeredCapital":"45334万元","compareEarnings":[{"period":"1week","weight":0.2138},{"period":"1month","weight":0.1739},{"period":"3month","weight":0.1133},{"period":"6month","weight":0.0871},{"period":"1year","weight":0.0727},{"period":"ytd","weight":0.1215}],"survey":"　　上海宣泰医药科技股份有限公司的主营业务是高端仿制药的研发、生产和销售以及CRO服务。公司的主要产品是高端仿制药、CRO服务。公司先后获得“上海市专利工作试点企业”、“上海市‘专精特新’中小企业”、“第四届上海知识产权创新奖专利二等奖”等荣誉。","serverTime":1728202764591,"listedPrice":9.37,"stockholders":"6994人(较上一季度减少4.38%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宣泰医药,688247,宣泰医药股票,宣泰医药股票老虎,宣泰医药股票老虎国际,宣泰医药行情,宣泰医药股票行情,宣泰医药股价,宣泰医药股市,宣泰医药股票价格,宣泰医药股票交易,宣泰医药股票购买,宣泰医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}